Drug Type Small molecule drug |
Synonyms 3-n-butylphthalide, Butylphthalide and Sodium Chloride, 728 + [6] |
Target |
Action inhibitors |
Mechanism KCNK inhibitors(Potassium two pore domain channel subfamily K inhibitors), Platelet aggregation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (30 Sep 2002), |
Regulation- |
Molecular FormulaC12H14O2 |
InChIKeyHJXMNVQARNZTEE-UHFFFAOYSA-N |
CAS Registry6066-49-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Butylphthalide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Stroke | China | 30 Sep 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Ischemic Stroke | Phase 3 | China | 25 Apr 2025 | |
ST Elevation Myocardial Infarction | Phase 3 | - | 01 Dec 2024 | |
Dementia, Vascular | Phase 3 | China | 29 Oct 2019 | |
Brain Ischemia | Phase 3 | China | 01 Jul 2011 | |
Ischemic stroke | Phase 2 | United States | 15 Jul 2022 | |
Peripheral Nerve Injuries | Phase 2 | China | 30 Mar 2022 | |
Peripheral Nerve Injuries | Phase 2 | China | 30 Mar 2022 |
Phase 1/2 | 84 | (Dl-3-n-butylphthalide) | pntzmyblui(regooakefy) = mpmimlrafl wufmmffbae (fbfnigrcrc, 2.48) View more | - | 18 May 2016 | ||
(Cerebrolysin) | pntzmyblui(regooakefy) = tmzhwmqodd wufmmffbae (fbfnigrcrc, 5.81) View more |